| Total | group A | group B | group C | P value* |
---|---|---|---|---|---|
(n = 79) | (n = 44) | (n = 19) | (n = 16) | ||
Age, years | Â | Â | Â | Â | 0.67 |
   ≥68 | 43 (54.4) | 23 (52.3) | 12 (63.2) | 8 (50.0) |  |
Gender | Â | Â | Â | Â | 0.72 |
   Male | 71 (89.9) | 39 (88.6) | 18 (94.7) | 14 (87.5) |  |
ECOG performance status | Â | Â | Â | Â | 0.46 |
   0 | 50 (63.3) | 29 (65.9) | 13 (68.4) | 8 (50.0) |  |
   1 | 29 (36.7) | 15 (34.1) | 6 (31.6) | 8 (50.0) |  |
hepatitis B surface antigen | 0.33 | ||||
   Positive | 27 (34.2) | 16 (36.4) | 4 (21.1) | 7 (43.8) |  |
hepatitis C virus antibody | 0.82 | ||||
   Positive | 34 (43.0) | 20 (45.5) | 7 (36.8) | 7 (43.8) |  |
Child-Pugh class (Child-Pugh score) | 0.064 | ||||
   A (5) | 21 (26.6) | 11 (25.0) | 7 (36.8) | 3 (18.8) |  |
   A (6) | 27 (34.2) | 19 (43.2) | 6 (31.6) | 2 (12.5) |  |
   B | 31 (39.2) | 14 (31.8) | 6 (31.6) | 11 (68.8) |  |
Vascular invasion | Â | Â | Â | Â | 0.097 |
   Positive | 26 (32.9) | 15 (34.1) | 3 (15.8) | 8 (50.0) |  |
Extra-hepatic spread | Â | Â | Â | Â | 0.62 |
   Positive | 43 (54.4) | 22 (50.0) | 12 (63.2) | 9 (56.3) |  |
AFP a, n (%) | Â | Â | Â | Â | 0.87 |
   ≥400 ng/mL | 29 (36.7) | 17 (38.6) | 6 (31.6) | 6 (37.5) |  |
Cause of failure of sorafenib treamtnet | 0.080 | ||||
   Tumor progression | 60 (75.9) | 37 (84.1) | 14 (73.7) | 9 (56.3) |  |
   Adverse effect | 19 (24.1) | 7 (15.9) | 5 (26.3) | 7 (43.8) |  |
Time to treatment failure of sorafenib, months | 0.059 | ||||
   <2.56 | 39 (49.4) | 20 (45.5) | 7 (36.8) | 12 (75.0) |  |
   ≥2.56 | 40 (50.6) | 24 (54.5) | 12 (63.2) | 4 (25.0) |  |